Thermo Fisher Scientific Inc.
NYSE•TMO
CEO: Mr. Marc N. Casper
Sector: Healthcare
Industry: Medical - Diagnostics & Research
Listing Date: 1980-03-17
Thermo Fisher Scientific Inc. provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the North America, Europe, Asia-Pacific, and internationally. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases; and solutions include biosciences, genetic sciences, and bio production to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets. Its Analytical Instruments segment provides instruments, consumables, software, and services for pharmaceutical, biotechnology, academic, government, environmental, and other research and industrial markets, as well as clinical laboratories. The company's Specialty Diagnostics segment offers liquid, ready-to-use, and lyophilized immunodiagnostic reagent kits, as well as calibrators, controls, protein detection assays, and instruments; immunodiagnostics develops, manufactures and markets complete bloodtest systems to support the clinical diagnosis and monitoring of allergy, asthma and autoimmune diseases; dehydrated and prepared culture media, collection and transport systems, instrumentation, and consumables; human leukocyte antigen typing and testing for organ transplant market; and healthcare products. Its Laboratory Products and Biopharma Services segment provides laboratory products, research and safety market channel, and pharma services and clinical research. It offers products and services through a direct sales force, customer-service professionals, electronic commerce, and third-party distributors under Thermo Scientific; Applied Biosystems; Invitrogen; Fisher Scientific; Unity Lab Services; and Patheon and PPD. It has a collaboration agreement with Mainz Biomed N.V. for the development of colorectal cancer screening product. Thermo Fisher Scientific Inc. was founded in 1956 and is headquartered in Waltham, Massachusetts.
Contact Information
Market Cap
$185.77B
P/E (TTM)
28.0
30.3
Dividend Yield
0.3%
52W High
$643.99
52W Low
$385.46
52W Range
Rank21Top 7.6%
6.0
F-Score
Modified Piotroski Analysis
Based on 10-year fundamentals
Strong • 6 / 9 points
Scoring Range (0-9)
8-9: Excellent Value
6-7: Strong Fundamentals
4-5: Average Quality
0-3: Weak Performance
Data Period: 2016-2025
Financial Dashboard
Q4 2025 Data
Revenue
$12.22B+7.20%
4-Quarter Trend
EPS
$5.22+8.98%
4-Quarter Trend
FCF
$2.99B+6.48%
4-Quarter Trend
2025 Annual Earnings Highlights
Key Highlights
Total Revenue Growth Total revenues reached $44.56B USD, marking 4% growth, driven by 2% organic expansion across segments.
Adjusted EPS Rises Adjusted EPS $22.87 USD, up 5%, driven by strong productivity improvements offsetting unfavorable business mix.
Strong Cash Generation Free Cash Flow totaled $6.34B USD, reflecting robust operating cash flow of $7.82B USD for the year.
Segment Organic Leaders Life Sciences Solutions and LPBS segments led organic revenue growth at 3% each for the fiscal year.
Risk Factors
Macroeconomic Instability Risks Business affected by general economic instability, inflationary pressures, and potential supply chain disruptions globally.
Goodwill Realization Risk Significant goodwill balance of $49.36B USD relies heavily on successful integration of recent acquisitions.
Evolving Regulatory Landscape Subject to complex, evolving global requirements concerning data privacy, cybersecurity, and trade compliance.
Supply Chain Vulnerabilities Reliance on sole/limited suppliers for certain materials risks production interruptions and increased logistics costs.
Outlook
Pending Clario Acquisition Planning close of Clario Holdings for approximately $8.88B cash plus contingent consideration mid-2026.
Future Restructuring Actions Expecting additional $250M restructuring charges primarily in 2026 across Laboratory Products and Life Sciences segments.
Strategic Investment Focus Continuing targeted spending on enhancing commercial capabilities, R&D, and expanding service offerings internally.
Projected 2026 Tax Rate GAAP effective tax rate projected to be between 7% and 9% for fiscal year 2026 based on current forecasts.
Peer Comparison
Revenue (TTM)
$65.01B
$58.74B
$56.15B
Gross Margin (Latest Quarter)
92.7%
81.9%
80.9%
Key Metrics
Symbol | Market Cap | P/E (TTM) | ROE (TTM) | Debt to Assets |
|---|---|---|---|---|
| NVS | $312.36B | 21.4 | 32.8% | 32.1% |
| AZN | $302.29B | 29.5 | 23.0% | 26.0% |
| MRK | $289.49B | 16.0 | 36.2% | 36.9% |
Long-Term Trends
Last 4 Quarters
Revenue
Net Income
Operating Cash Flow
4Q Revenue CAGR
5.6%
Steady Growth
4Q Net Income CAGR
9.4%
Profitability Improving
Cash Flow Stability
100%
Strong Cash Flow
Deep Research
Next earnings:Apr 21, 2026
EPS:-
|Revenue:-
Financials
Earnings Calls
Reports
News
Income Statement
Balance Sheet
Cash Flow Statement
Ratios
% Chg.
Income Statement | LTM |
|---|
No Data